DCE-MRI Based on 4D Free Breathing for Predicting Preoperative Neoadjuvant Chemoradiotherapy for Esophageal Cancer

Not Applicable

Recruiting

• Conditions: Esophageal Cancer

• Registration Number: NCT06755866
• Lead Sponsor: Yunnan Cancer Hospital

Brief Summary

To prospectively collect medical images and clinical data related to esophageal cancer using 4D Free Breathing DCE-MRI technology, to evaluate the image quality in the diagnosis of esophageal cancer, and to predict the efficacy of preoperative neoadjuvant chemoradiotherapy for esophageal cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-11-26
• Status Verified: 2024-12
• Study First Submitted: 2024-12-15
• Study First Submitted QC: 2024-12-24
• Last Update Submitted: 2024-12-24
• Study First Posted: 2025-01-01
• Last Update Posted: 2025-01-01
• Primary Completion: 2026-07-31
• Study Completion: 2026-07-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 135

Inclusion Criteria

1. Be 18 years of age and older;
2. First diagnosis of esophageal squamous cell carcinoma confirmed by histopathological biopsy;
3. The clinical stage is cT1b~cT2N+; or the clinical stage is cT3~cT4 any N, (thoracic esophageal cancer, esophagogastric junction cancer);
4. There are no contraindications to MRI examination

Exclusion Criteria

1. Have other primary tumors;
2. The image quality does not meet the diagnostic criteria;
3. Those who do not cooperate with the inspection;
4. Patients who have received prior chemoradiotherapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Tumor response assessment	Surgery was performed within one month after neoadjuvant therapy, and the pathological pCR of the pathological results obtained from the surgery was used as the gold standard in this study to evaluate tumor treatment response	This study aims to assess tumor treatment response using pathology gold standard pCR . pCR refers to the state in which the pathological tumor completely disappears after systemic therapy, such as chemotherapy, targeted therapy, or endocrine therapy.

Trial Locations

Locations (1)

Yunnan Cancer Hospital; 🇨🇳 Kunming City, Yunnan, China